Cholesterol reduction and stroke occurrence: An overview of randomized clinical trials

Cerebrovascular Diseases

Volumn 10, Issue 2, 2000, Pages 85-92

  Di Mascio, Rocco ^a   Marchioli, Roberto ^a   Tognoni, Gianni ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cholesterol; Meta analysis; Meta regression; Stroke

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; STATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SECONDARY PREVENTION; STROKE;

ANTICHOLESTEREMIC AGENTS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; FEMALE; HUMANS; INCIDENCE; MALE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0033951190     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016035     Document Type: Article

References (61)

1. Holme I: Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995;76:10C-17C.
2. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol reduction yields clinical benefit: A new look at old data. Circulation 1995;91:2274-2282.
3. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ: Stroke, statins, and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-950.
4. Crouse JR III, Byington RP, Hoen HM, Furberg CD: Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 278:313-321.
5. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol loweing with statin drugs, risk of stroke, and total mortality. JAMA 1997;278: 313-321.
6. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB: Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized, controlled trials. Ann Intern Med 1993;119:136-145.
7. Hebert PR, Gaziano JM, Hennekens CH: An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995;155:50-55.
8. Controlled trial of soya-bean oil in myocardial infarction. Report of a Research Committee to the Medical Research Council. Lancet 1968:ii: 693-770.
9. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U: A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969; 39/40(suppl 2):1-63.
10. Leren P: The Oslo Diet Heart Study: Eleven year report. Circulation 1970;42:935-942.
11. Trial of clofibrate in the treatment of ischaemic heart disease. Five year study by a group of physicians of the Newcastle-upon-Tyne Region. BMJ 1971;4:767-775.
12. Ischaemic heart disease: A secondary prevention trial using clofibrate. Report by a Research Committee of the Scottish Society of Physicians. BMJ 1971;4:775-784.
13. Acheson J, Hutchinson EC: Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis 1972;15:177-183.
14. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
15. Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB: Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and morality. J Chron Dis 1978;31:5-14.
16. Report from the Committee of Principal Investigators: A co-operative trial in the prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-1118.
17. McCaughan D: The long-term effects of probucol on serum lipid levels. Arch Intern Med 1981;141:1428-1432.
18. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results: Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
19. Frick MH, Elo H, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA: Helsinki Heart Study: Primary-prevention trial with gemofibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
20. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;357: 3233-3240.
21. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1998;223:405-418.
22. Frantz ID Jr, Dawson EA, Ashman PL, Gatewood LC, Bartsch GE, Kuba K, Brawer ER: Test of effect of lipid lowering by diet on cardiovascular risk: The Minnesota Coronary Survey. Arteriosclerosis 1989;9:129-135.
23. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick FV, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
24. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bisset JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990;323:946-955.
25. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012.
26. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H: Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.
27. Singh RB, Rastogi SS, Verma R, Laxmi B, Singh R, Ghosh S, Niaz MA: Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: Results of one year of cardioprotective diet in patients with recent acute myocardial infarction: Results of one year follow up. MBJ 1992; 304:1015-1019.
28. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
29. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Manttari M, Manninen V: Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med 1993;25:41-45.
30. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group: Coronary angiongraphic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-976.
31. The Pravastatin Multinational Study Group for Cardiac Risk Patients: Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/ dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-1037.
32. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Letkowitz DS, Probstfield J, Riley WA, Young B, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-1687.
33. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Laspérance J, the CCAIT Study Group: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
34. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
35. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-1459.
36. MAAS Investigators: Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344: 633-638.
37. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinsky AS, King SB III, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ, O'Neill WW, Frazier JE II, Cohen-Bernstein CL, Robbins DC, Brown CL III, Alexander RW, and the Lovastatin Restenosis Trial Study Group: Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331: 1331-1337.
38. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995;75:455-459.
39. Salonen R, Nyssonen K, Prokkala E, Rummukainen J, Belder R, Park JS, Salonen JT: Kuopio Atherosclerosis Prevention Study (KAPS): A population-based primary prevention trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758-1764.
40. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI, on behalf of the REGRESS Study Group: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-2540.
41. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME, for the PLAC I Investigators: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-1139.
42. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301-1307.
43. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
44. Kroon AA, Aengevaeren WRM, van der Werf T, Ujien GJH, Reiber JHC, Bruschke AVG, Stalenhoef AFH: LDL-Apheresis Atherosclerosis Regression Study (LAARS): Effects of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-1835.
45. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutheford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Event Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
46. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
47. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kasaniemi YA, Pasternack A, Taskinen MR, for the Lopid Coronary Angiography Trial (LOCAT) Study Group: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997;96:2137-2143.
48. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
49. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and after myocardial infarction: An overview of randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
50. DerSimonian R, Laird N: Meta-analysis in clinical trials. Controlled Clin Trials 1986;7: 177-188.
51. Tell GS, Crouse JR, Furberg CD: Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. Stroke 1988;19: 423-430.
52. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD, for the MRFIT Research Group: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989;320:904-910.
53. Yano K, Reed DM, Maclean CJ: Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989;20:1460-1465.
54. Qizilbash N, JOnes L, Warlow C, Mann J: Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic stroke. BMJ 1991;303:605-609.
55. Di Mascio R, Marchioli R, Vitullo F, Di Pasquale A, Cavasinni L, Tognoni G, on behalf of Progetto 3A Investigators: Serum cholesterol and risk of ischemic stroke: Results of a case-control study. Prev Med 1995;24:128-133.
56. Giroud M, Creisson E, Fayolle H, André N, Becker F, Martin D, Dumas R: Risk factors for primary cerebral hemorrhage: A population-based study - The Stroke Registry of Dijon. Neuroepidemiology 1995;14:20-26.
57. Hachinsky V, Graffagnino C, Beaudry M, Bernier G, Buck C, Donner A, Spence D, Doig G, Wolfe BMJ: Lipid and stroke: A paradox resolved. Arch Neurol 1996;53:303-308.
58. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-1653.
59. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 1996;348:1079-1082.
60. Marchioli R, Marfisi RM, Carinci F, Tognoni G: Meta-analysis, clinical trials, and transferability of research results into practice: The case of cholesterol-lowering inteventions in the secondary prevention of coronary heart disese. Arch Intern Med 1996;156:1158-1172.
61. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 1998;97:946-952.